English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17744/20032 (89%)
Visitors : 7322455      Online Users : 277
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32230


    標題: Evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma A single institution experience
    作者: Ke, Te-Min
    Fong, Yao
    Lin, Li-Ching
    Chien, Yu-Wun
    Yang, Ching-Chieh
    Lin, Chia-Hui
    Lin, Kuei-Li
    Que, Jenny
    貢獻者: Chi Mei Med Ctr, Dept Radiat Oncol
    Chi Mei Med Ctr, Dept Thorac Surg
    Chung Hwa Univ Med Technol, Dept Optometry
    Taipei Med Univ, Sch Med
    Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Publ Hlth
    Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
    關鍵字: chemoradiotherapy
    esophageal squamous cell carcinoma
    radiation dose
    日期: 2018-11
    上傳時間: 2019-11-15 15:46:01 (UTC+8)
    出版者: LIPPINCOTT WILLIAMS & WILKINS
    摘要: The optimal radiation dose for definitive chemoradiotherapy in inoperable esophageal squamous cell carcinoma (ESCC) has been long debated. In this study, we evaluated the effect of doses greater than the conventional radiation dose (50.4 Gy) on tumor control, tumor response, overall survival (OS), and disease-free survival (DFS). The database of patients diagnosed with inoperable ESCC from 2007 to 2015 was obtained from the cancer registry of Chi-Mei Medical Center. All categorical variables were compared using Chi-squared test. The risk of OS and DFS were estimated using Cox proportional hazards regression, and Kaplan-Meier plots presented the trend of OS and DFS with log-rank tests used to compare differences. All significance levels were set at P<.05. A total of 84 patients were retrospectively analyzed, with 42 (50%) receiving > 50.4 Gy and 42 (50%) receiving <= 50.4 Gy (50%) concurrently with chemotherapy. Univariate and multivariate analysis revealed no significant differences between higher dose and conventional dose in OS (P=.21) and DFS (P=.26). Further dose analysis of < 50, 50 to 50.4, 51 to 60, and > 60 Gy showed no significant differences in OS or DFS. Higher doses conveyed no significant benefit on the failure pattern, either local regional failure or distant failure (P=.42). Major prognostic factors associated with better OS on multivariate analysis were stages I and II patients (P=.03) and radiation technique using arc therapy (P=.04). No acute toxicity of grade III or higher was recorded. The results of our study show that providing higher than conventional radiation doses concurrent with chemotherapy for inoperable ESCC does not impact OS or DSF, nor does it improve locoregional failure or distant failure. Although tumor response might be improved by radiation doses > 50.4 Gy, the impact on OS and DFS remain to be studied.
    link: http://dx.doi.org/10.1097/MD.0000000000013214
    關聯: Medicine, v.97, n.46, e13214
    Appears in Collections:[藥學系(所)] 期刊論文
    [醫務管理系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1097-MD.0000000000013214.pdf469KbAdobe PDF73View/Open
    index.html0KbHTML152View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback